News Galderma Announces FACE by Galderma™ – a Game-Changing Augmented Reality Solution Helping Healthcare Professionals Increase Their Activities and Improve Patient Satisfaction
-
FACE by Galderma™ is a cutting-edge aesthetic visualization application that uses the digital face to evaluate the results of simulated injection treatments in real time
-
The app provides advanced wrinkle detection and possible results from 19 injection treatments displayed as dynamic “before and after” images
-
The solution provides a comprehensive approach to personalized care, enabling patients to execute their treatment plan with confidence
-
In a global pilot study, 80% of respondents said the app helped them understand their treatment options.Meanwhile, 85% said they would recommend the app and 91% said they plan to go back to their doctor to continue their treatment plan1
Zug, Switzerland, January 26, 2023–(BUSINESS WIRE)–Galderma announces the launch of FACE by Galderma™, an innovative augmented reality application. This breakthrough solution enables aesthetic practitioners and patients to visualize treatment results during the planning phase. The technology will be presented to the aesthetic science community at the 2023 World Congress of the International Master’s Program in Aging Science (IMCAS) in Paris, January 26-28.
FACE by Galderma™ provides patients with a real-time, true “before and after” view of possible outcomes for a personalized treatment plan.This helps address concerns about the end result, while also allowing for a better understanding of the overall treatment approach, ultimately improving patient satisfaction1.
|
“We developed this game-changing solution to support aesthetic practitioners and allow patients to visualize what they can expect from the procedures included in their treatment plans. For example, real-time injection results function to simulate how a treatment enhances a patient’s lips , cheek or chin. Galderma™’s FACE provides patients with realistic visuals of results before treatment begins, supporting them in identifying treatment goals and priorities with their physician. It gives them the freedom to achieve their aesthetic goals.” Gerry Muller Head of Global Business Unit, Aesthetics |
FACE by Galderma™ allows for an immersive, fully interactive consultation process and enables the beauty practitioner to assess the entire face in real time. The assessment is based on Galderma’s five-point assessment, which takes into account skin quality, facial shape, facial symmetry, facial proportions and contours, as well as animation and emotional expression. Following the assessment, priority areas can be identified and an individualized treatment plan can be created. By taking a whole-face approach, FACE by Galderma™ ensures practitioners provide a holistic treatment plan that meets the needs of the patient. The technology behind FACE by Galderma™ was developed in collaboration with Crisalix, the world’s leading reference in 3D, virtual reality and augmented reality aesthetic simulations.
|
“FACE by Galderma™ has pioneered a level of innovation never before seen in the aesthetic industry. This unique technology has the potential to change the way consultations are conducted and is ideally suited to showcase the possibilities of Galderma’s impressive portfolio of injectables.” Jamie Garcia |
The results of a recent global pilot study conducted by Galderma™ on FACE are very promising. Of those surveyed, 80% said the app helped them understand their treatment options, while 73% agreed it made them consider procedures they hadn’t previously considered. Meanwhile, 61 percent said they planned to show their friends their “before and after” photos.Overall, 85% said they would recommend the app and 91% said they planned to go back to their doctor to continue their individualized treatment plan1.
|
“Patients come to my clinic because they are interested in cosmetic injection procedures and often have questions and concerns about how the procedure will turn out and whether it will look natural and address their wrinkles. Galderma’s FACE tool is available for me through new advanced technology of patients simulated their results prior to surgery, which should help alleviate their concerns and build trust.” Alexandra Belavik Nurse Practitioner and Beautician Syringe Regency Medical Spa and Hair Clinic in Barrington, IL |
Galderma™’s FACE has 19 potentially injectable outcomes using products from Galderma’s portfolio (depending on local indication), enabling patients to see simulated visual effects in real time. Treatment options include:
-
Neuromodulators, such as DYSPORT®blue® (EU) and ALLUZIENCE® (First ready-to-use liquid botulinum toxin type A, approved for use in Europe (excluding Greece, Lithuania, Estonia, Latvia and Hungary) in June 2021).
-
Biostimulators, including SCULPTRA®
-
Line of Hyaluronic Acid Fillers, RESTYLANE® He Ruilan® skin booster
The tool also facilitates patient management, acting as a “patient passport”. It enables clinics to store all patient records in one place, including treatment plans, “before and after” videos and images, and appointment schedules. Patients can also access their FACE through their Galderma™ account and view their personal patient profile from home.
FACE by Galderma™ will be launched in the US and Brazil in the first half of 2023, with a global rollout in Latin America, Europe, Middle East, Canada and Asia in 2023.
About Galderma
Galderma is a leader in specialty dermatology with a presence in approximately 90 countries. We offer an innovative, science-based portfolio of premium flagship brands and services covering all segments of the rapidly growing dermatology market through aesthetic injectables, dermocosmetic and therapeutic dermatology. Since our founding in 1981, we’ve focused on the body’s largest organ – the skin – partnering with healthcare professionals to meet the needs of individual consumers and patients, and achieve exceptional outcomes. Because we understand that the skin we live in affects our lives, we’re advancing dermatology with every skin story. For more information, visit: www.galderma.com
About Crisalix
Crisalix is the online international simulation and imaging standard before and after cosmetic, reconstructive or skin treatments, supporting healthcare professionals and educating patients in making choices. Thanks to our disruptive online imaging solutions, powered by state-of-the-art artificial intelligence and computer vision technologies, our exclusive platform is used throughout the patient journey by patients, leading medical aesthetic brands and the most recognizable healthcare providers. With undefeated key improvements to major medical data and related business metrics, we are focused on enhancing the beauty journey of people around the world, day in and day out, through game-changing 3D, 4D, virtual reality and augmented reality visualizations.
About Alluzience® (liquid botulinum toxin type A)
Alluzience (liquid botulinum toxin type A) is the first ready-to-use BoNT-A liquid neuromodulator formulation launched in Europe. Alluzience should only be administered by physicians with appropriate qualifications and expertise in this treatment, using the required equipment.2 Dosage and treatment intervals are based on assessment of individual patient response.2 Treatment intervals should not exceed once every three months.2 For more information, see Product Feature Summary.2
Alluzience is a licensed product from Ipsen. Alluzience is a registered trademark of Ipsen. Galderma has an exclusive license to Ipsen to develop, market and distribute Alluzience for approved indications in multiple European countries.
About Movement Disorders® / Azure®
Dysport (abobotulinumtoxinA) is a prescription injection used to temporarily improve the appearance of moderate to severe frown lines (glabellar lines) between the eyebrows in adults younger than 65 years of age. Dysport is also marketed as Azzalure3 Used in the EU for the treatment of frown lines and lateral canthal lines. Dysport has more than 30 years of clinical experience in therapeutic indications and 13 years of clinical experience in cosmetic indications worldwide, with extensive clinical evidence of safety and efficacy. It is licensed in 85 markets worldwide for cosmetic indications, and Dysport is one of the world’s leading brands of cosmetic neuromodulators, delivering over 100 million treatments to date in cosmetic indications.
Dysport is a licensed product from Ipsen and is manufactured by them. Since 2009, Galderma and Ipsen have entered into a strategic partnership under which Galderma promotes and distributes Ipsen’s botulinum toxin type A products for cosmetic indications. The Ipsen-Galderma strategic partnership now covers China, the US, Europe and the Middle East, Australia, South Korea, Canada, Brazil, Argentina and several other countries. Ipsen continues to promote Dysport in certain therapeutic indications in countries around the world. For more information about Ipsen, please visit www.ipsen.com.
About Ruilan®
RESTYLANE is the original non-animal stabilized hyaluronic acid filler with over 25 years of accomplishment and over 50 million treatments worldwide. NASHA™ and OBT™ technologies make RESTYLANE the world’s most diverse line of fillers for truly personalized results.4,5
Ryce blue® The product portfolio includes RESTYLANE®Ruilan® LYFT™, Restylane® KYSSE™, Restylane® VOLYME™, Rayblue® DEFYNE™, Rayblue® REFYNE™, Rayblue® EYELIGHT™ and RESTYLANE® SKINBOOSTERS VITAL™.
about sculpture®
SCULPTRA stimulates the skin’s own collagen production6 Indicated to increase volume in sunken areas, especially to correct skin sunken areas such as skin lines, wrinkles, folds and scars, as well as signs of skin aging.7 SCULPTRA is also indicated for mass correction of signs of facial fat loss (lipoatrophy).7
SCULPTRA is an injectable biostimulant containing microparticles of poly-L-lactic acid (PLLA) that gradually activates the structural foundation of the skin, providing up to 25 months of natural appearance and long-term results.8 SCULPTRA was first approved in Europe in 1999 and is currently available in more than 40 countries around the world.
refer to
1. FACE App Patient Pilot Study, November 2020-September 2021.170 patients from 12 countries surveyed
2. Alluzience Product Feature Summary, June 10, 2021
3. Azzalure SmPC
4. Archive data (MA-33939)
5. Poster presented by Öhrlund A. at AMWC 2019
6. Bohnert K et al. Plast Reconstr Surg 2019;127(4):1684–92
7. Sculpture instruction manual. 2018
8. Brown SA et al. Plast Reconstr Surg 2011;127(4):1684–92
View source releases on businesswire.com: https://www.businesswire.com/news/home/20230125005814/en/
contact person
media
Christian Marcoux, MSc
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50
rachel mooney
Global Franchise Newsletter
rachel.mooney@galderma.com
+41 76 261 64 41
sebastian cross
Director of Corporate Communications
sebastien.cros@galderma.com
+41 79 529 59 85
